Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Churchill Discovers 20 Gold-Silver-Molybdenum-Lead-Zinc Veins Within a 150m Wide Swarm at Pomley Cove Pond, Black Raven Property